Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.45 |
| ▸ | KARS1 | Q15046 | 3/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.45 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 1/20 | 0.44 |
| ▸ | SKP1 | P63208 | 1/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144874 | 0.93 | HDAC6 (0.50) | ALOX15DHODHP2RY12USP30SSTR5 | |
| SCHEMBL10144828 | 0.90 | P2RY12 (0.50) | P2RY12USP30 | |
| SCHEMBL10144834 | 0.84 | HPGDS (0.44) | PDGFRAKARS1KITDHODHUSP30 | |
| SCHEMBL20460316 | 0.79 | ALOX15 (0.63) | ALOX15DHODHNPC1RAB9AMAPT | |
| SCHEMBL20460359 | 0.79 | ALOX15 (0.63) | ALOX15DHODHNPC1RAB9AMAPT | |
| SCHEMBL3311625 | 0.74 | CKS1B (0.57) | USP30NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL10144884 | 0.71 | HDAC6 (0.50) | USP30NPC1RAB9AALDH1A1LMNA | |
| SCHEMBL6139645 | 0.71 | CKS1B (0.61) | USP30NPC1RAB9ACKS1BSKP1 | |
| SCHEMBL12233018 | 0.71 | CHRNB2 (0.50) | P2RY12 | |
| SCHEMBL16048031 | 0.70 | CKS1B (0.60) | USP30NPC1RAB9ACKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394831-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-8394831-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2013-03-12 | — | — | US | disclosed |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-16 | — | — | US | disclosed |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA, NV (BE) | 2012-02-16 | — | — | US | disclosed |
| US-8071615-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-8071615-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2009-02-12 | — | — | US | disclosed |
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | VAN EMELEN KRISTOF | 2009-02-12 | — | — | US | disclosed |
| US-7446109-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-04 | — | — | US | disclosed |
| US-7446109-B2 | Carbonylamino-derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042920-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | ALOX15 4727/4885PDGFRA 3374/4885KARS1 342/4885 |
| US-20120041001-A1 | CARBONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | ALOX15 4727/4885PDGFRA 3374/4885KARS1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.